$KALA - Good entry only after stabilizing above 4.68

Clinical trial for EYSUVIS (KPI-121) - top line results of Phase III expected on first Q of 2020.
The concern is :
cash position as of September 30 was $97.6 million, compared to $170.9 million as of December 31, 2018.

I do not suggest to buy\sell .
Good-luck